Initial romiplostim dosing and time to platelet response in patients with treatment refractory immune thrombocytopenia.

about

Initial romiplostim dosing and time to platelet response in patients with treatment refractory immune thrombocytopenia.

Item

http://www.wikidata.org/entity/Q47213468

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Initial romiplostim dosing and ...... ctory immune thrombocytopenia.

@en

Initial romiplostim dosing and ...... ctory immune thrombocytopenia.

@nl

type

Item

label

Initial romiplostim dosing and ...... ctory immune thrombocytopenia.

@en

Initial romiplostim dosing and ...... ctory immune thrombocytopenia.

@nl

prefLabel

Initial romiplostim dosing and ...... ctory immune thrombocytopenia.

@en

Initial romiplostim dosing and ...... ctory immune thrombocytopenia.

@nl

P1476

Initial romiplostim dosing and ...... ctory immune thrombocytopenia.

@en

P2093

Lauren Levine

http://www.w3.org/2001/XMLSchema#string

Ryan K DasGupta

http://www.w3.org/2001/XMLSchema#string

Spero Cataland

http://www.w3.org/2001/XMLSchema#string

Tracy Wiczer

http://www.w3.org/2001/XMLSchema#string

P2860

Overwhelming infection in asplenic patients: current best practice preventive measures are not being followed

International consensus report on the investigation and management of primary immune thrombocytopenia

The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia

Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trial.

Immune thrombocytopenic purpura.

Relationship between platelet count and bleeding risk in thrombocytopenic patients.

AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP.

Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP.

Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials.

Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial.

P304

1078155217748470

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1078155217748470

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29298625

http://www.w3.org/2001/XMLSchema#string

P921

thrombocytopenia